Guideline for the Treatment of Hypothyroidism in Prematurity

Mahin Hashemipour1, Afagh Hassanzadeh Rad2, Setila Dalili2

  • 1Department of Pediatrics, School of Medicine, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.

Insights

Congenital hypothyroidism is a common infant endocrine disorder. This guideline addresses screening and treatment confusion in premature neonates to aid timely clinical decisions.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Neonatology

Background:

  • Congenital hypothyroidism (CH) is a frequent endocrine disorder in infants and children.
  • Thyroid hormone is crucial for the function of most organs.
  • Thyroid abnormalities are common, though often transient, in premature neonates.

Purpose of the Study:

  • To provide a guideline for clinicians regarding congenital hypothyroidism in neonates.
  • To address the confusion surrounding screening timing and treatment of hypothyroidism in premature infants.
  • To facilitate rapid and accurate clinical decision-making in cases of neonatal hypothyroidism.

Main Methods:

  • Guideline development based on existing literature and expert consensus.
  • Review of current practices for screening and treatment of CH in term and premature neonates.
  • Analysis of differing viewpoints on managing hypothyroidism in prematurity.

Main Results:

  • Significant differences exist in appropriate screening times for premature versus term neonates.
  • Current guidelines lack definitive protocols for treating hypothyroidism in premature infants.
  • There are varied clinical viewpoints on managing this condition in prematurity.

Conclusions:

  • The guideline aims to resolve confusion regarding CH screening and treatment in neonates.
  • It provides support for timely clinical decisions, particularly for premature infants.
  • Standardized approaches are needed to manage CH effectively in this vulnerable population.

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.5K
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
3.4K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
22
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
35
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
443
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
302